PACS GROUP INC (PACS)
US69380Q1076 - Common Stock
PACS gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 113 industry peers in the Health Care Providers & Services industry. PACS has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, PACS is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year PACS was profitable.
1.2 Ratios
With a decent Return On Assets value of 2.90%, PACS is doing good in the industry, outperforming 69.03% of the companies in the same industry.
PACS has a better Return On Equity (19.73%) than 92.04% of its industry peers.
The Return On Invested Capital of PACS (4.38%) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.9% | ||
| ROE | 19.73% | ||
| ROIC | 4.38% |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
PACS's Profit Margin of 3.63% is fine compared to the rest of the industry. PACS outperforms 76.11% of its industry peers.
PACS has a Operating Margin of 6.68%. This is in the better half of the industry: PACS outperforms 72.57% of its industry peers.
Looking at the Gross Margin, with a value of 21.33%, PACS is in line with its industry, outperforming 47.79% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 6.68% | ||
| PM (TTM) | 3.63% | ||
| GM | 21.33% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so PACS is destroying value.
PACS has about the same amout of shares outstanding than it did 1 year ago.
PACS has a worse debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 2.32 indicates that PACS is not a great score, but indicates only limited risk for bankruptcy at the moment.
The Altman-Z score of PACS (2.32) is better than 61.06% of its industry peers.
A Debt/Equity ratio of 0.90 indicates that PACS is somewhat dependend on debt financing.
PACS has a Debt to Equity ratio of 0.90. This is in the lower half of the industry: PACS underperforms 66.37% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.9 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 2.32 |
ROIC/WACC0.51
WACC8.6%
2.3 Liquidity
A Current Ratio of 1.71 indicates that PACS should not have too much problems paying its short term obligations.
PACS has a better Current ratio (1.71) than 63.72% of its industry peers.
A Quick Ratio of 1.71 indicates that PACS should not have too much problems paying its short term obligations.
The Quick ratio of PACS (1.71) is better than 68.14% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.71 | ||
| Quick Ratio | 1.71 |
3. Growth
3.1 Past
The earnings per share for PACS have decreased strongly by -25.00% in the last year.
PACS shows a strong growth in Revenue. In the last year, the Revenue has grown by 28.47%.
EPS 1Y (TTM)-25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)28.47%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
Based on estimates for the next years, PACS will show a very strong growth in Earnings Per Share. The EPS will grow by 41.69% on average per year.
Based on estimates for the next years, PACS will show a quite strong growth in Revenue. The Revenue will grow by 18.69% on average per year.
EPS Next Y24.19%
EPS Next 2Y55.87%
EPS Next 3Y41.69%
EPS Next 5YN/A
Revenue Next Year28.75%
Revenue Next 2Y22.77%
Revenue Next 3Y18.69%
Revenue Next 5YN/A
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 40.80 indicates a quite expensive valuation of PACS.
The rest of the industry has a similar Price/Earnings ratio as PACS.
PACS is valuated rather expensively when we compare the Price/Earnings ratio to 30.20, which is the current average of the S&P500 Index.
With a Price/Forward Earnings ratio of 16.71, PACS is valued correctly.
Based on the Price/Forward Earnings ratio, PACS is valued a bit cheaper than the industry average as 61.06% of the companies are valued more expensively.
PACS is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 23.28, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 40.8 | ||
| Fwd PE | 16.71 |
4.2 Price Multiples
The rest of the industry has a similar Enterprise Value to EBITDA ratio as PACS.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 30.51 |
4.3 Compensation for Growth
The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
PACS's earnings are expected to grow with 41.69% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.69
PEG (5Y)N/A
EPS Next 2Y55.87%
EPS Next 3Y41.69%
5. Dividend
5.1 Amount
No dividends for PACS!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
PACS GROUP INC
NYSE:PACS (11/4/2024, 8:28:34 PM)
After market: 31.25 +0.24 (+0.77%)31.01
-11.93 (-27.78%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap4.81B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 40.8 | ||
| Fwd PE | 16.71 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)1.69
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.9% | ||
| ROE | 19.73% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 6.68% | ||
| PM (TTM) | 3.63% | ||
| GM | 21.33% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.8
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.9 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.71 | ||
| Quick Ratio | 1.71 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-25%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y24.19%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)28.47%
Revenue growth 3YN/A
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y